| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
| Targets |
Amlodipine besilate impurity G is a structural analog of amlodipine and is expected to act on L-type voltage-dependent calcium channels. As a calcium channel antagonist, it may have potential application in the study of neurological diseases. However, its primary use is as an impurity reference standard for pharmaceutical analysis rather than as a therapeutic agent.
|
|---|---|
| ln Vitro |
As an impurity reference standard, this compound is not evaluated for pharmacological activity in vitro. Its primary use is in analytical chemistry for the identification, quantification, and quality control of amlodipine besilate in pharmaceutical formulations. In vitro activity data are limited, but it may serve as a model compound for studying calcium channel antagonism.
|
| ln Vivo |
This compound is not administered in vivo as a therapeutic agent. Its relevance is confined to pharmaceutical quality control and regulatory submissions. It does not possess significant pharmacological activity that would be evaluated in vivo. Any in vivo effects would be related to its presence as an impurity in amlodipine formulations, which are strictly controlled.
|
| Enzyme Assay |
The in vitro analytical procedure for amlodipine besilate impurity G typically involves high-performance liquid chromatography (HPLC) with UV detection. The compound is used as a reference standard to identify and quantify the impurity in amlodipine besilate samples. Its retention time and peak area are compared against a calibration curve to determine the impurity level, ensuring compliance with pharmacopoeial specifications.
|
| Cell Assay |
This compound is not used in cellular assays, as it is an impurity standard rather than a pharmacologically active substance. Its application is exclusively in chemical analysis for pharmaceutical quality control. No cellular activity data are available or relevant for this compound.
|
| Animal Protocol |
In vivo animal studies are not conducted for this impurity standard, as it is not a therapeutic agent. Its use is limited to analytical and regulatory purposes in pharmaceutical development. The compound does not have a pharmacological profile that would warrant in vivo testing.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to this compound as an impurity reference standard. It is not administered as a drug, and its absorption, distribution, metabolism, or excretion are not studied. Its relevance is purely analytical in the context of pharmaceutical quality control.
|
| Toxicity/Toxicokinetics |
Toxicological data for amlodipine besilate impurity G are limited, as it is not a therapeutic agent. Its presence is controlled as an impurity to ensure patient safety. The compound is considered a process-related impurity that must be monitored and controlled to meet regulatory limits, thereby minimizing any potential toxicological risk associated with its presence in amlodipine formulations.
|
| References | |
| Additional Infomation |
Amlodipine besilate impurity G (CAS 43067-01-2) is a calcium channel antagonist with potential application in the study of neurological diseases. It has the molecular formula C17H18ClNO4 and a molecular weight of 335.78. It is also known as Dimethyl 4-(2-Chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate. This impurity is commonly used as a reference standard in pharmaceutical research and quality control.
|
| Molecular Formula |
C17H18NO4CL
|
|---|---|
| Molecular Weight |
335.78212
|
| Exact Mass |
335.092
|
| Elemental Analysis |
C, 60.81; H, 5.40; Cl, 10.56; N, 4.17; O, 19.06
|
| CAS # |
43067-01-2
|
| Related CAS # |
43067-01-2;
|
| PubChem CID |
737062
|
| Appearance |
Solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
436.7±45.0 °C at 760 mmHg
|
| Flash Point |
217.9±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
3.83
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
529
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2Cl)C(=O)OC
|
| InChi Key |
REIGLQUFMMOAFU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18ClNO4/c1-9-13(16(20)22-3)15(11-7-5-6-8-12(11)18)14(10(2)19-9)17(21)23-4/h5-8,15,19H,1-4H3
|
| Chemical Name |
dimethyl 4-(2-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
|
| Synonyms |
Amlodipine besilate impurity G; RUN 67012; RUN-67012; RUN67012
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9781 mL | 14.8907 mL | 29.7814 mL | |
| 5 mM | 0.5956 mL | 2.9781 mL | 5.9563 mL | |
| 10 mM | 0.2978 mL | 1.4891 mL | 2.9781 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
